Cytology and Biomarkers in NMIBC
Cystoscopy and cytology remain the standard for diagnosis, but a plethora of urinary biomarkers could someday be a useful adjunct to NMIBC surveillance.
Bladder Cancer
FEATURES
Latest Bladder Cancer News
Mitomycin C May Reduce Urothelial Recurrence Risk in UTUC
In a small study, single-dose instillation of mitomycin C immediately following therapeutic ureteroscopy for upper tract urothelial carcinoma was associated with an 87% decreased risk of urothelial recurrence.
Ureteroscopy Prior to UTUC Surgery Ups Intravesical Recurrence Risk
Preoperative diagnostic ureteroscopy (URS) before radical nephroureterectomy for upper tract urothelial carcinoma (UTUC) is a risk factor for intravesical recurrence, according to investigators. In a study of 453 patients with UTUC undergoing radical nephroureterectomy (RNU), a significantly higher proportion of patients who underwent preoperative URS experienced intravesical recurrence (IVR) than those who did not (43.8%…
Epidural Use in Radical Cystectomy Cases Tied to Worse Perioperative Outcomes
Patients who receive epidural anesthesia at the time of radical cystectomy, compared with those who do not, are more likely to have a myocardial infarction and to be readmitted to a hospital within 30 days following surgery.
Risk Factors for UTUC Intravesical Recurrence Identified
Tumor diameter and stage are independent risk factors for intravesical recurrence of organ-confined upper tract urothelial carcinoma (UTUC) following radical nephroureterectomy (RNU), according to a new study. In a retrospective study of patients with organ-confined UTUC who underwent RNU combined with bladder cuff resection, investigators propensity score matched 42 patients who experienced intravesical recurrence (IVR)…
Combination Therapy for Advanced Urothelial Carcinoma Shows Promise in Early Clinical Trial
A combination of pembrolizumab and an antibody-drug conjugate demonstrated a 73% overall response rate in a phase 1/2 clinical trial.
Neoadjuvant Immune-Chemotherapy Has Positive Effect in MIBC Cases
Combination neoadjuvant therapy with nivolumab and gemcitabine-cisplatin in patients with muscle-invasive bladder cancer resulted in significant pathologic downstaging at radical cystectomy, with manageable toxicities.
Novel Bladder Cancer Salvage Therapy Appears Safe, Effective
Nadofaragene firadenovec, a novel gene-mediated therapy, achieved a 53.4% complete response rate in patients with high-grade carcinoma in situ unresponsive to bacillus Calmette-Guérin, phase 3 trial results show.
MMR Deficiency Rare in Urothelial Cancers, but Linked to Immune Response
More studies needed to understand role of MMR deficiency as biomarker of immune response.
OS Benefit Seen for Disease Downstaging With Neoadjuvant Chemotherapy vs Transurethral Resection in Muscle-Invasive Bladder Cancer
Two approaches to downstaging muscle-invasive bladder cancer prior to radical cystectomy include neoadjuvant chemotherapy and transurethral resection.
Bladder Cancer Surgery Safe Following Neoadjuvant Immunotherapy
Toxicity profile and readmission rates among patients who underwent radical cystectomy and pelvic lymph node dissection following neoadjuvant pembrolizumab are in line with previously published series reporting 90-day outcomes after RC with or without neoadjuvant chemotherapy.
Want to read more?
Please login or register first to view this content.
Next post in Bladder Cancer
